Academic partners

NeuroBasic-PharmaPhenomics The NeuroBasic-PharmaPhenomics consortium consists of 11 academic partners and 6 companies. Most of the members were involved in the previous NeuroBSIK-MousePhenomics project. This core has now been complemented by academic partners who are specialized in neuropharmacology and/or statistical analyses of complex data sets and by companies who deliver new high throughput approaches to the PharmaPhenomics screening pipeline and integrate the projects in drug discovery programs. Below is a brief introduction of each academic partner.

1. Prof. Dr. Chris De Zeeuw – head of the Dept. of Neuroscience at Erasmus MC / project Director of the Netherlands Institute for Neuroscience (NIN) in Amsterdam

He studied genotype-phenotype relations of different brain diseases including Fragile X, Williams-Beuren syndrome, Cockayne syndrome and calcium channelopathies. He is chair of the Neuro-BSIK Mouse Phenomics consortium and the designated chair of the new NeuroBasic-PharmaPhenomics consortium. He will develop new mouse models for brain diseases and provide assays for evaluation of their motor behavior.

2. Dr. Christiaan Levelt – heading the mouse transgenics department at the Netherlands Institute for Neuroscience in Amsterdam.

He studies signal transduction networks involved in plasticity and development of the visual system. He will study molecular, electrophysiological and anatomical aspects of plasticity in mousemodels of brain disease.

3. Prof. Dr. Matthijs Verhage – head of the Department of Functional Genomics at the Center for Neurogenomics and Cognitive Research (CNCR) of the Vrije Universiteit in Amsterdam, vice-chair of the current Neuro-BSIK con- sortium and designated vice-chair of the new consortium

He studies signal transduction pathways involved in transmitter release. He will analyze synaptic phenotypes of genetic and pharmacological perturbations and the link to behavioral phenotypes.

4. Prof. Dr. Guus Smit – heads the Department of Molecular and Cellular Neurobiology at the CNCR / director of the Amsterdam- Rotterdam School for Neurosciences and responsible for the Ph.D. training programs.

He is an expert on synaptic proteomics and cellomics in animal models of disease and will contribute high-content molecular and cellular endophenotypes of novel mouse models.

5. Prof. Dr. Gerard Borst – vice-chair of the Dept. of Neuroscience at Erasmus MC

He studies synaptic function and development of sensory systems. He will perform in vivo and in vitro assays of synaptic function and development in mouse models for brain diseases and use these assays to test drug effectiveness.

6. Prof. Dr. Huib Mansvelder – head of the Department of Integrative Neurophysiology at the CNCR

He studies neuronal networks and synaptic plasticity. He will contribute to uncovering relationships between neurological and psychiatric diseasespecific phenograms, molecular pathways involved and electrophysiological signatures of neuronal network functioning. He will also test drug effectiveness at early stages of diseases of cerebral cortical function.

7. Prof. Dr. Ype Elgersma – head of the ENCORE expertise center for neuro-developmental disorders at Erasmus MC

He studies molecular mechanisms underlying plasticity and learning in mouse models of neuro-developmental disorders. He coordinated clinical trials on new drug targets in children with cognitive disorders and is currently involved in a clinical trial assessing the effects of new drug targets for intellectual disabilities. He will develop new mouse models for neurological diseases, identify new drug targets and instigate new clinical trials.

8. Prof. Dr. Steven Kushner – professor of Neurobiology in the Department of Psychiatry of Erasmus MC

He is both a board-eligible psychiatrist and a molecular biologist. He will translate promising treatment strategies identified in mouse models of neuropsychiatric disorders into human clinical trials.

9. Prof. Dr. Roger Adan – neuropharmacologist chairing the CNS section of TI-Pharma as well as the section neurobiology of behavior of the Department of Neuroscience and Pharmacology at the RMI, UMC Utrecht

He is an expert in drug target validation in rat models of autonomic CNS diseases. He will validate new drug targets by employing adult rat models that have been genetically modified with the use of viral vector technology.

10. Prof. Dr. Cajo ter Braak – biometrician at Biometris of Wageningen University and Research Centre

His main interest is in prediction in high-dimensional data and networks. He will investigate new statistical methods and develop algorithms for the analysis of complex multivariate data resulting from high-throughput behavioral phenotyping studies.